Tags: thyroid | cancer | drug | Bayer | Nexavar | FDA

Thyroid Cancer Drug Gets Fast-Tracked for Approval

Tuesday, 27 August 2013 07:49 AM

Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday.
 
The U.S. Food and Drug Administration aims to complete the priority review within six months, rather than the standard review of about 10 months, Bayer said.
 
Bayer and development partner Onyx Pharmaceuticals are seeking a wider use for Nexavar to include treatment of patients with thyroid cancer that returned despite previous surgery and treatment with radioactive iodine, a group with a particularly poor prospect of survival.
 
Nexavar is already approved to treat liver as well as kidney cancer and it is also being tested on breast cancer patients.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday. The U.S. Food and Drug Administration aims to complete the priority review...
thyroid,cancer,drug,Bayer,Nexavar,FDA
118
2013-49-27
Tuesday, 27 August 2013 07:49 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved